Elements of cancer immunity and the cancer–immune set point

Daniel S. Chen and Ira Mellman ()
Additional contact information
Daniel S. Chen: Genentech, 1 DNA Way
Ira Mellman: Genentech, 1 DNA Way

Nature, 2017, vol. 541, issue 7637, 321-330

Abstract: Abstract Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting that a broader view of cancer immunity is required. Immunity is influenced by a complex set of tumour, host and environmental factors that govern the strength and timing of the anticancer response. Clinical studies are beginning to define these factors as immune profiles that can predict responses to immunotherapy. In the context of the cancer-immunity cycle, such factors combine to represent the inherent immunological status — or 'cancer–immune set point' — of an individual.

Date: 2017
References: Add references at CitEc
Citations: View citations in EconPapers (31)

Downloads: (external link)
https://www.nature.com/articles/nature21349 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:541:y:2017:i:7637:d:10.1038_nature21349

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature21349

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().